Clinical correlations with EGFR circulating tumor DNA testing in all-stage lung adenocarcinoma
Cancer Biomarkers · 2023
DOI: 10.3233/cbm-220079 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Biomarkers, 2023. Verfasst von Pimpin Incharoen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Circulating Tumor DNA, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Information on genetic alterations, notably EGFR mutations, is important for guiding non-small-cell lung cancer (NSCLC) treatment. Circulating tumor DNA (ctDNA) analysis represents a less invasive alternative to tissue biopsy for analyzing mutation status, but its clinical value may vary across disease stages. OBJECTIVE: To explore clinical correlates of ctDNA and tissue/plasma-based EGFR mutation (EGFRm) status across all NSCLC stages. METHODS: Ninety patients were analyzed, representing three cohorts: newly-diagnosed early-stage, advanced-stage, and recurrent NSCLC. Relationships among clinical/surgical parameters, ctDNA, EGFRm status, and survival outcomes were analyzed. RESULTS: Plasma/tissue EGFRm concordance was lower in early-stage (58.6%) than in advanced-stage patients (87.5%). In early-stage patients, ctDNA levels were variable and not significantly associated with clinical/surgical parameters. In advanced-stage patients, time to EGFR-TKI treatment failure (TTF), but not overall survival (OS), was significantly longer in EGFRm-positive vs. EGFRm-negative patients. In patients with recurrent disease, 40% of plasma samples were EGFRT790M-positive at recurrence. In T790M-positive patients, we noted slight trends toward longer OS with vs. without osimertinib treatment and longer OS and TTF with second-line vs. later-line osimertinib. CONCLUSIONS: Our results affirm the use of ctDNA testing in advanced-stage and recurrent NSCLC. Further studies on osimertinib as early-line therapy, clinical correlates and the utility of plasma-based testing in early-stage NSCLC are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
- Research Center, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
- Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
- Department of Mathematics, Faculty of Science and Technology, Rajamangala University of Technology Suvarnabhumi, Nonthaburi, Thailand.
- Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Zitieren
APA
Incharoen, P., Jinawath, A., Arsa, L., Kamprerasart, K., Trachu, N., Monnamo, N., Khiewngam, K., Muntham, D., Chansriwong, P., Sirachainan, E., & Reungwetwattana, T. (2023). Clinical correlations with EGFR circulating tumor DNA testing in all-stage lung adenocarcinoma. Cancer Biomarkers. https://doi.org/10.3233/cbm-220079
Vancouver
Incharoen P, Jinawath A, Arsa L, Kamprerasart K, Trachu N, Monnamo N, et al. Clinical correlations with EGFR circulating tumor DNA testing in all-stage lung adenocarcinoma. Cancer Biomarkers. 2023. doi:10.3233/cbm-220079
BibTeX
@article{Incharoen2023,
author = {Incharoen, Pimpin and Jinawath, Artit and Arsa, Lalida and Kamprerasart, Kaettipong and Trachu, Narumol and Monnamo, Nanamon and Khiewngam, Khantong and Muntham, Dittapol and Chansriwong, Phichai and Sirachainan, Ekaphop and Reungwetwattana, Thanyanan},
title = {Clinical correlations with EGFR circulating tumor DNA testing in all-stage lung adenocarcinoma},
journal = {Cancer Biomarkers},
year = {2023},
doi = {10.3233/cbm-220079}
}
EUVIMED